Caballero et al. 2024 | 1

# Identification of moderate effect size genes in autism spectrum disorder through a novel gene pairing approach

Madison Caballero<sup>1</sup>, F Kyle Satterstrom<sup>3,4,5</sup>, Joseph D. Buxbaum<sup>1,2,6,7,8,9</sup>, and Behrang
Mahjani<sup>1,2,6,7,10,11,12,\*</sup>

- <sup>1</sup>Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- <sup>2</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- <sup>3</sup>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA,
   USA
- <sup>4</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- <sup>5</sup>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital,
   Boston, MA, USA
- <sup>6</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- <sup>7</sup>The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- <sup>8</sup>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- <sup>9</sup>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- <sup>10</sup>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai,
   New York, NY, USA.
  - <sup>11</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  - <sup>12</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

### 24 25 26

23

6 7

8

\* Corresponding author: behrang.mahjani@mssm.edu

#### 27 28

### 29 Abstract

30

31 Autism Spectrum Disorder (ASD) arises from complex genetic and environmental factors, with 32 inherited genetic variation playing a substantial role. This study introduces a novel approach to uncover moderate effect size (MES) genes in ASD, which individually do not meet the ASD 33 34 liability threshold but collectively contribute when paired with specific other MES genes. 35 Analyzing 10,795 families from the SPARK dataset, we identified 97 MES genes forming 50 36 significant gene pairs, demonstrating a substantial association with ASD when considered in 37 tandem, but not individually. Our method leverages familial inheritance patterns and statistical 38 analyses, refined by comparisons against control cohorts, to elucidate these gene pairs' 39 contribution to ASD liability. Furthermore, expression profile analyses of these genes in brain 40 tissues underscore their relevance to ASD pathology. This study underscores the complexity of ASD's genetic landscape, suggesting that gene combinations, beyond high impact single-gene 41 42 mutations, significantly contribute to the disorder's etiology and heterogeneity. Our findings pave 43 the way for new avenues in understanding ASD's genetic underpinnings and developing 44 targeted therapeutic strategies.

45

### 46 Introduction

- 48 Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterized by
- 49 challenges in social interaction and communication, as well as a tendency toward restricted and

50 repetitive behaviors. Extensive research has underscored the complex interplay of genetic and environmental factors contributing to its risk <sup>1-6</sup>. Diverse environmental influences, including 51 52 pregnancy complications, parental age, pollutants, and socioeconomic status, contribute to the overall risk of ASD<sup>7</sup>. Nonetheless, there is consensus that genetic factors exert greater 53 influence on ASD's etiology, underscored by its substantial heritability exceeding 50%<sup>2,8</sup>. Large-54 scale genomic studies have further revealed that ASD is a polygenic disorder influenced by a 55 56 broad spectrum of genetic variants rather than a single gene mutation<sup>9</sup>. These variants, ranging 57 in effect sizes, collectively shape the likelihood and clinical manifestations of ASD. The 58 threshold liability model for ASD, defined by an individual's unique combination of genetic and 59 environmental factors, has become the predominant way to understand and evaluate the 60 complex interplay of influences contributing to ASD risk and manifestation. Thus, the likelihood 61 of developing ASD is dependent on whether the summation of these factors crosses the 62 threshold for an ASD phenotype.

63

Genetic factors contributing to ASD liability range in rarity and effect size. Inherited common 64 variants (those with a population frequency of at least 1%) explain approximately 50% of 65 individual ASD liability <sup>1,2,6</sup>. Though common variants play a substantial role when considered 66 together, an individual common variant provides little contribution to individual ASD liability and 67 68 often offers little biological insight. The pressure of negative selection forces variants that 69 individually confer substantial heritability for ASD to be rare in the population; thus, studies of 70 rare variants – ranging from single nucleotide variants to large structural changes – have been 71 undertaken to help identify risk genes and developmental pathways. In recent years, research 72 efforts have focused on identifying de novo mutations in particular. De novo loss-of-function 73 variants are rare in the general population, particularly in genes which are haploinsufficient or 74 which exhibit evolutionary constraint. Genes in which such variants are overrepresented in 75 individuals with ASD can be identified as ASD risk genes, and the variants themselves can confer extreme phenotypes that provide meaningful biological insight <sup>3,4</sup>. However, *de novo* 76 mutations only account for approximately 5% of ASD cases<sup>2</sup>, and their sporadic origin renders 77 78 them less representative of ASD's overall heritability. 79

While there are an estimated 1100 genes implicated in ASD<sup>10</sup>, only a few hundred have been 80 confidently identified <sup>3,4,6,11</sup>. Rare variant analyses aggregate variants across a gene and employ 81 82 advanced statistical models such as the Transmission and De Novo Association (TADA) test <sup>12</sup>. 83 TADA increases statistical power by combining de novo mutations and case-control inherited 84 variants while incorporating per-gene mutation rates and gene constraint scores like the loss-offunction tolerance <sup>13,14</sup>. Driven by variants of large effect, TADA has significantly improved the 85 identification of genes associated with ASD<sup>4</sup>. A notable set of genes, namely SCN2A, SHANK3, 86 87 CHD8, ADNP, and SYNGAP1, demonstrate especially compelling evidence, as deleterious 88 variants within these genes are effectively absent in control groups. However, this approach 89 loses power when considering genes where deleterious variants have a smaller effect size, as 90 these variants are more frequently found in non-ASD controls. As a result, there is a gap in our 91 understanding of genes where variants make moderate contributions to ASD liability. 92 93 Here we propose and implement a novel method for identifying moderate effect size (MES) 94 genes. We define MES genes as genes that individually do not surpass the ASD liability threshold when disrupted and therefore have no significant association when tested in isolation 95 96 (Fig 1A). However, when deleterious variants in one gene co-occur with deleterious variants in

a specific second MES gene (always in concert with common genetic variation and
environmental factors), their cumulative contributions can cross the liability threshold. This does
not imply that gene pairs are epistatic or form dependent gene-gene interactions. Instead, we

100 find paired genes are predominantly independent with co-occurrence being strongly associated

with ASD. Thus, our strategy targets genes with meaningful but not singular impacts on ASDliability.

103

104 The process of testing gene combinations poses a statistical challenge, particularly given the 105 vast number of potential gene pairs. For example, with 20,000 protein-coding genes, the 106 number of two-gene combinations is approximately 200 million, necessitating an extremely 107 stringent significance threshold. To overcome this challenge, we selected candidate pairs based 108 on familial inheritance patterns of ultra-rare deleterious variants, narrowing the focus to a 109 manageable subset of potential risk genes. Subsequent statistical analysis on this subset aimed 110 to detect gene pairs more prevalent in individuals with ASD compared to non-ASD controls. 111 After establishing statistical significance and validating findings, we then characterized 97 112 predicted MES genes to further support their roles in ASD etiology and heterogeneity.

- 113
- 114
- 115 **Results**

### 116


### 117 Identification of candidate MES genes inherited as pairs

118

119 Our search for MES genes began by identifying pairs of candidate genes through family-based 120 inheritance patterns. This approach circumvents conducting approximately 200 million pairwise 121 comparisons among all protein-coding genes which would impose a harsh significance 122 threshold set by multiple testing corrections. Our primary objective was to identify instances 123 where inherited variants in two distinct genes were overrepresented in offspring with ASD, with 124 non-ASD offspring potentially inheriting either variant, but not both. This streamlined approach 125 enabled us to focus on candidate gene pairs exhibiting the most promising associations with 126 ASD. 127

128 The first and second steps of our candidate screen focused on the identification of familial structures wherein ultra-rare (frequency <0.1%) deleterious variants in two genes were inherited 129 130 by all offspring with ASD within a given family (Fig 2; Fig 1B). In this context, the term 'A\*' 131 designates an ultra-rare deleterious genetic alteration in a gene present in one parent, with the 132 potential for transmission to the offspring. The second step searched for mirrored inheritance 133 patterns involving an ultra-rare deleterious variant in a different gene, denoted as 'B\*'. In such 134 instances, 'B\*' originates from the parent who did not transmit 'A\*', thereby maintaining genetic 135 independence. We then filtered to instances where all ASD offspring that share the same 136 parents exhibited 'A\*B\*' inheritance, while none of their non-ASD siblings carried both alleles. In 137 different families, the specific ultra-rare deleterious variants in genes were predominantly 138 distinct. Additionally, as there were instances of multiple 'A\*' or 'B\*' variants within the same 139 gene and family, we used the count of unique families rather than unique sites for identifying 'A\*B\*' pairs. We initially analyzed 10,795 families from the SPARK<sup>15</sup> iWES v1 dataset ("SPARK 140 141 v1", comprising waves WES1-WES4), each with both parents and at least one ASD offspring 142 genotyped with whole exome sequencing data (WES; see Methods). For deleterious ultra-rare 143 variants (gnomAD<sup>16</sup> v3 non-neuro allele frequency of <0.1%), families on average exhibited an 144 'A\*' inheritance pattern for 94 different genes.

Caballero et al. 2024 | 4




147 148 149 Figure 1. Discovery and enrichment of MES genes. (A) Hypothesized role of individual MES genes 150 and their cumulative influence on the genetic liability of ASD in an individual. (B) Example inheritance 151 pattern illustrating ultra-rare deleterious variants in two genes within the parents (depicted in blue or 152 green) that are exclusively jointly inherited by offspring with ASD. This exemplifies a potential genetic 153 mechanism contributing to ASD susceptibility. (C) Mean number of rare (<1%) or ultra-rare (<0.1%) 154 deleterious variants in SPARK parents versus gene size. The red line represents linear regression. 155 Without TTN, correlation is 0.71 and 0.80, respectively. (D) Equilibrium probability and Bayes factors for 156 the predicted MES gene pairs in ASD. Bars in blue denote an equilibrium probability  $<3.03 \times 10^{-4}$  or a 157 Bayes factor >100. (E) Enrichment of predicted MES genes per tissue relative to all protein-coding genes. 158

159

146

### Caballero et al. 2024 | 5



161 162 163

### Figure 2. Flowchart of steps involved in MES gene discovery.

164

165 In the third step, to identify promising gene pairs for further analysis, we assessed the likelihood 166 167 of observing specific patterns of mirrored 'B\*' inheritance within families displaying 'A\*' inheritance. This entailed calculating the likelihood of ultra-rare deleterious 'B\*' variants 168 169 manifesting in a second gene, contingent upon our knowledge of the prevalence of such 170 variants in the population. For instance, let us consider 'GeneA' which features 'A\*' inheritance 171 in seven families, and 'GeneB,' another gene with 'B\*' inheritance in 20 families. Among these, four families exhibited the aforementioned mirrored 'A\*B\*' inheritance pattern. Utilizing the 172 binomial distribution and adjusting by the frequency of ultra-rare deleterious variants per gene in 173 the SPARK parent population, we determined (1) the expected frequency of observing this four-174 175 in-seven and, conversely, four-in-twenty arrangement, and (2) the relative likelihood that the 176 genes observed were 'GeneA' and 'GeneB' (see Methods). This latter step is essential as genes with longer coding sequences generally have a greater frequency of ultra-rare or rarer 177 178 deleterious variants (Pearson's r. 0.84; 0.76 for rare or rarer variants; Fig1C). To illustrate, 'A\*' 179 inheritance patterns within the large gene TTN were observed in 32.0% of all SPARK families. Consequently, the occurrence of a mirrored 'A\*B\*' inheritance pattern with TTN is considerably 180 181 more anticipated than with SNAP25, a small gene where 'A\*' inheritance patterns were present 182 in only 0.048% of the SPARK families. 183

We retained 1,916 pairs of genes where the normalized expected frequency was less than one in both 'A\*' and 'B\*' configurations (**Table S1**). Additionally, in the fourth step, for each candidate pair, we imposed the condition that at least three families must exhibit the 'A\*B\*' inheritance pattern. To refine candidate pairs, we required that there were no occurrences of 'A\*B\*' in the remaining non-ASD individuals within the broader SPARK dataset, which comprised 36,323 individuals sequenced with WES. This filtering process resulted in a final count of 164 candidate pairs from 316 unique protein coding genes (**Table S1**).

191

Of note, we tested additional variant types and frequencies, including missense variants and
 PTVs of rare (<1%) frequency and analyses restricted to only PTVs (see **Methods**). We
 selected PTVs and missense variants of ultra-rare or rarer frequency for the following analyses
 as it produced the greatest number of candidate pairs after SPARK family filtering.

Caballero et al. 2024 | 6

#### 198 199

200 Though SPARK includes individuals without ASD, all are within families where at least one 201 individual has ASD. This makes these individuals an inaccurate representation of the general 202 population. Therefore, to perform statistical analyses below that incorporate the population 203 frequency of ultra-rare deleterious variants by gene, we included individuals without ASD or 204 other known mental, behavioral, or neurodevelopmental disorders. This included 3,202 individuals from the 1000 genomes project (1kGP)<sup>17,18</sup>, 156,550 individuals from the All of Us 205 (v7) consortium, and 16,586 individuals from the BioMe Biobank. As with SPARK, we identified 206 207 ultra-rare deleterious variants in the 316 candidate MES genes in these cohorts. Lacking familial 208 information for most individuals, we could not determine with certainty whether any variant was 209 inherited or *de novo*. However, given that there are approximately 70 *de novo* mutations per 210 genome per generation<sup>19</sup>, we can assume that variants observed in these cohorts are almost 211 always inherited.

Statistical assessment of MES genes and incorporating non-neuro cohorts

212

213 To ensure comparability of detected variants in the 1kGP, All of Us, and BioMe cohorts as 214 controls, we examined the frequency of ultra-rare deleterious variants within the candidate MES 215 genes across these cohorts. Positive correlations were observed among all cohorts, with a more 216 pronounced correlation in cohorts characterized by larger sample sizes (Fig S1). Notably, non-217 ASD individuals in the SPARK cohort displayed a slightly higher burden of ultra-rare deleterious 218 variants per gene compared to individuals in the other cohorts. On average, candidate genes in 219 the SPARK cohort contained 0.02%, 0.12%, and 0.18% more variants than in the All of Us, 220 BioMe, and 1kGP cohorts, respectively. Across all cohorts, SPARK showed a notable and 221 consistent enrichment for ultra-rare deleterious variants in UGT2B11, AFAP1L2, C20orf141, and 222 OLAH (Fig S1). However, these genes also contained relatively more synonymous variants in the SPARK cohort, suggesting their enrichment for deleterious variants is not biologically 223 224 meaningful. Of note, variants in ZNF717 were highly enriched in 1kGP compared to the other 225 cohorts (5.74-8.78% more). However, this gene's role in cellular proliferation and the 226 lymphoblastoid cell line source of 1kGP suggest these variants may be somatic and under 227 positive selection.

228

Among the 212,661 individuals without ASD, 'A\*B\*' was conspicuously absent in 26 out of the 164 candidate pairs and occurred in only two or fewer individuals in 83 candidate pairs. Across all candidate pairs, the incidence of 'A\*B\*' was consistently higher among individuals with ASD than their non-ASD counterparts. Notably, in 71 pairs, the frequency of 'A\*B\*' was more than 10 times greater in individuals with ASD. Together, this illustrates a pronounced disequilibrium between individuals with ASD and those without ASD.

235

236 Our above search (encompassing steps one through four in Fig 2) aimed to identify potential 237 MES genes for in-depth analysis, mitigating the influence of large genes with a high frequency 238 of ultra-rare deleterious variants. In the fifth and final step, our objective was to assess the 239 statistical significance of the skew in MES gene pairs in relation to ASD. We hypothesized that 240 the concurrent inheritance of ultra-rare deleterious variants in two paired MES genes was 241 strongly associated with ASD development. We anticipated that the prevalence of 'A\*B\*' in the 242 population would adhere to an expected equilibrium, being the product of 'A\*' and 'B\*' 243 frequencies in the population. Their significant enrichment in individuals with ASD is presumably 244 the result of their involvement in ASD etiology. In contrast, our null hypothesis is that the 245 overrepresentation of 'A\*B\*' in individuals with ASD, contingent upon the individual frequencies 246 of 'A\*' and 'B\*' in the population, occurred by chance. Furthermore, when examining the 247 frequency of 'A\*' or 'B\*' in isolation, we required that neither gene may be significantly 248 overrepresented (p<0.05) in the individuals with ASD. Therefore, with respect to ASD, we

Caballero et al. 2024 | 7

required only 'A\*B\*' to be in strong disequilibrium.

250

251 To illustrate, consider ultra-rare deleterious variants in the genes SNAP25 (as 'A\*') and SLPI (as 252 'B\*'). which are present in 0.056% and 0.196% of individuals, respectively. Notably, these 253 frequencies do not show significant differences when gueried in individuals with or without ASD 254 (0.053% versus 0.057% for SNAP25 and 0.220% versus 0.192% for SLPI, respectively). At 255 equilibrium, 'A\*B\*' should occur at a frequency determined by the product of their individual 256 frequencies. For SNAP25 and SLPI, 'A\*B\*' occurs in three of 34,164 individuals with ASD and in none of the 212,661 individuals without ASD. Using the cumulative density function of the 257 258 binomial distribution, we calculated the probability of observing at least three individuals with ASD having 'A\*B\*' and none without ASD to be 6.88x10<sup>-6</sup>. We calculated this equilibrium 259 260 probability for all 164 paired candidate MES genes. For 33 pairs, 'A\*B\*' was significantly overrepresented in individuals with ASD (p<3.03x10<sup>-4</sup>, corrected for multiple testing). We 261 262 discarded seven candidate pairs where an individual gene in isolation was significantly 263 overrepresented in individuals with ASD.

264

265 We additionally calculated the Bayes factor for each pair. As described above, our null 266 hypothesis posits that the increased occurrence of 'A\*B\*' in individuals with ASD is a random 267 event occurring at the equilibrium probability observed above. Our alternate hypothesis is that 268 'A\*B\*' is enriched among individuals with ASD precisely because it results in an ASD 269 phenotype. Therefore 'A\*B\*' would be more at equilibrium when not considering ASD status. 270 Using the example of SNAP25 and SLPI, the Bayes factor was 400, strongly supporting the 271 alternate hypothesis. Interestingly, one of the largest Bayes factors was 5,807 for the genes 272 PITX3, a gene with a known role in dopaminergic neuron differentiation, and C20orf141, a gene 273 of unknown function. Across the 164 paired candidate MES genes, 46 had a Bayes factor 274 greater than 100. 275

We retained 50 candidate gene pairs (97 unique genes) where the equilibrium probability was
<3.03x10<sup>-4</sup> or the Bayes factor was >100 (Fig 1D; Table S1). Importantly, the genes in pairs
showed statistically significant associations to ASD but not when tested in isolation. From here,
we will refer to these as 'predicted MES genes'.

According to the recent and most comprehensive screens for ASD genes<sup>4</sup>, the mean ASD FDR of the predicted MES genes was 0.804, demonstrating that single MES genes by themselves are not generally associated with ASD. Only one gene, *DEDD*, had an ASD FDR <0.05. Six genes (*PUF60, SNAP25, PSMC3, CAMK2B,* and *HIST1H4J*) were associated with neurodevelopmental disorders (FDR <0.05) though not for ASD. Similarly, the 97 MES genes were also not associated with ASD in other major studies <sup>3,10,11,20</sup> and are therefore not considered consensus ASD-associated genes.

288

The median probability of being loss-of-function intolerant (pLI) score of the predicted MES 289 290 genes was 0.029 and only 15 genes were >0.9, the common threshold for extreme 291 haploinsufficiency. When breaking up genes by probability of pLI decile, MES genes inhabited more moderate deciles than large effect size genes characterized in the most recent 292 comprehensive assessment of ASD genes <sup>4</sup> (Fig S2). This was also the same result for loss-of-293 294 function observed over expected upper bound fraction (LOEUF) scores (Fig S2). This suggests 295 the predicted MES genes are not strongly constrained and are more haplosufficient. This is 296 again consistent with our model of MES genes where each gene alone is not evidently 297 associated with ASD. Importantly, deleterious variants in both copies of predicted MES genes 298 are not present nor assessed in this study. Loss-of-function in both copies of a MES gene could 299 produce a separate pathological phenotype. Nonetheless, we present 97 predicted MES genes

Caballero et al. 2024 | 8

that when disrupted in concert with a second MES gene are strongly associated with ASD.

302

### 303 Validations of MES genes

304

To mitigate the challenge of a highly stringent multiple testing correction threshold inherent in comparing every protein-coding gene, we streamlined our analysis to focus on candidate gene pairs. This approach, while efficient, raises concerns of bias due to selective inference, as it prioritizes pairs of genes with a pre-established likelihood of association. To address potential bias, we implemented two validation strategies: (1) conducting a replication study using synonymous variants as a neutral benchmark, and (2) incorporating additional ASD samples.

311

312 Our initial validation utilized ultra-rare synonymous variants, which, due to their non-functional 313 impact, were anticipated to yield fewer or less significant associations with ASD. This analysis 314 was conducted identically to that for deleterious variants. We found a similarly strong correlation 315 between the quantity of ultra-rare synonymous variants and CDS length (Pearson r: 0.83), as 316 well as between the counts of ultra-rare synonymous and deleterious variants (r: 0.82; Fig S3 A, 317 **B**). Moreover, the variability in the frequency of ultra-rare synonymous variants across different 318 cohorts paralleled that observed for missense variants (Fig S3C), affirming that synonymous 319 variants replicate our analyses under the same conditions. Utilizing ultra-rare synonymous 320 variants, we identified merely five gene pairs (10 unique genes; **Table S1**), in contrast to the 50 321 pairs identified with deleterious variants. Together, this suggests a potential false-positive rate of 322 approximately 10%.

323

Further validation involved a new cohort of 36,997 samples from SPARK iWES v2 ("SPARK v2", 324 325 adding WES5), including 10,128 ASD individuals. Applying the same methodological 326 framework, we first reassessed the equilibrium tests using only the new SPARK samples. 327 However, only eight of the original 50 gene pairs could be validated as we required A\*B\* in at 328 least one individual with ASD. Among the eight, seven pairs met the criteria of an equilibrium 329 probability p<0.05 or a Bayes Factor >10, adjusted for the smaller independent dataset (Fig 330 **S4A**). None of the five pairs identified with ultra-rare synonymous variants could be validated. In 331 addition, by combining data from both the SPARK v1 and v2 cohorts, we found 38 of the original 50 pairs maintained significance (equilibrium probability  $<3.03 \times 10^{-4}$  or a Bayes factor >100: 332 Table S1; Fig S4B). By contrast, only two synonymous variant pairs retained significance post-333 334 combination, none surpassing a significance level of 1.2x10<sup>-4</sup>, a stark contrast to the maximum significance of 5.9x10<sup>-8</sup> observed in the primary analysis with ultra-rare deleterious variants 335 336 (Table S1).

337

To summarize, our methodology efficiently identifies MES genes while maintaining a low falsepositive rate. Of the initial 50 gene pairs, 38 (74 unique genes) were corroborated by integrating
the SPARK v2 dataset, with seven out of eight subjected to independent validation using
SPARK v2. Subsequent analyses will delve into the 97 unique genes within these pairs,
focusing on their expression patterns and phenotypes among carriers as further evidence of
their involvement in ASD.

344 345

### 346 Enrichment of MES gene expression in the brain

347

To further our identification of MES genes implicated in ASD, we conducted an analysis of their tissue expression profiles. While ASD etiology encompasses factors beyond neural influences,

Caballero et al. 2024 | 9

such as those associated with the gut microbiome <sup>21</sup>, it is imperative that genes contributing to 350 ASD development exhibit expression in the brain. Accordingly, we hypothesized that our 351 352 predicted MES genes would exhibit an enrichment for expression in brain tissues. Utilizing 353 consensus normalized expression values (nTPM) from the Human Protein Atlas (v23)<sup>22</sup>, and 354 encompassing 50 tissues, we observed that 77.0% of the 20,151 protein coding genes 355 demonstrated detectable expression (nTPM > 1) in at least one brain tissue, with 70.5%356 exhibiting expression in the cerebral cortex. Strikingly, among the 97 predicted MES genes, 357 85.6% displayed detectable expression in at least one brain tissue, and 79.4% specifically in the 358 cerebral cortex. To assess the statistical significance of these findings, we performed random 359 gene sampling and quantified per-tissue expression, revealing a significant overrepresentation 360 of predicted MES genes in the cerebral cortex (p=0.022) and the adrenal glands (p=0.009) (Fig 361 1E; Fig S5A). The predicted MES genes did not exhibit significant underrepresentation in any 362 tissues. Among the 74 unique genes that maintained significance with the addition of SPARK 363 v2, we observed the same cerebral cortex and adrenal gland enrichment. Furthermore, we did 364 not observe that the predicted MES genes were expressed at a significantly higher level than 365 other cerebral cortex or adrenal expressed genes. Nonetheless, the observed enrichment of 366 MES gene expression in the cerebral cortex aligns with our initial predictions. The enrichment in 367 the adrenal glands was unexpected but not unprecedented as increases in androgen and cortisol levels, which are both secreted by the adrenal glands, are associated with ASD <sup>23,24</sup>. 368 369

370 To conduct a more in-depth investigation, we queried gene expression within 193 subregions of 371 the brain (Fig S5B). Notably, we identified the most pronounced enrichment of the 97 predicted 372 MES genes in the ventral tegmental area and central amygdala, although the statistical 373 significance fell just below the conventional threshold (p=0.08 and p=0.07, respectively). Again, 374 the same pattern was observed with the 74 unique genes that maintained significance with 375 SPARK v2. It is noteworthy that these particular brain regions exhibited the highest proportion of 376 MES genes with detectable expression (83.5% for both regions), surpassing the expression 377 levels observed in other brain regions or any alternative tissues that we analyzed. The 97 378 predicted MES genes are not canonically associated with ASD because they do not show 379 strong associations when tested alone. Yet, their expression is most pronounced in a region of the brain linked to psychiatric disorders including ASD <sup>25,26</sup>. Together, we showed the predicted 380 381 MES genes are characterized by expression in neural tissues, suggesting their disruptions may 382 result in psychiatric phenotypes.

- 383
- 384
- 385

#### 386 Phenotypes of non-ASD carriers of MES genes

387 While MES genes were identified in pairs, the nature of their contribution to ASD remained 388 ambiguous - whether each gene within a pair independently influenced ASD or, conversely, if 389 their impact stemmed from interdependent gene-gene (GxG) interactions. In the scenario of 390 independent contributions, the disruption of a single MES gene may manifest mild ASD-like 391 phenotypes, while the disruption of two MES genes could result in an additive or synergistic 392 effect. In contrast, within the context of dependent GxG interactions, the disruption of a single 393 MES gene yields no discernible phenotype. To observe if any predicted MES pairs show 394 independent contributions, we queried the phenotypes and questionnaire responses of non-395 ASD individuals within the SPARK v1 cohort. Per our MES gene discovery methodology, non-396 ASD individuals may have an ultra-rare deleterious variant in either gene (herein simply referred 397 to as 'carriers') of an MES gene pair – but never both.

398 We first examined responses from the Social Communication Questionnaire (SCQ), completed

399 for adolescent offspring with and without ASD. The SCQ, comprising 40 yes-or-no guestions 400 designed for ASD screening, was available for 3,831 non-ASD offspring in our study. We 401 focused on 68 out of the 97 predicted MES genes that exhibited a minimum of five non-ASD 402 MES gene carriers with SCQ responses. For each gene and each SCQ guestion, we employed a  $\chi^2$  test to compare responses between carriers and non-carriers among the non-ASD 403 404 offspring. We found 31 out of the 68 tested genes exhibited a significant (p<0.05) skew for at 405 least one SCQ question. For 15 genes, more than one question exhibited significantly increased 406 ASD-like responses, with a maximum of six questions per gene. In total, 65 questions 407 demonstrated significant skew, with 63 revealing a higher frequency of ASD-like responses in 408 carriers compared to non-carriers (Fig S6). Our results remained consistent when comparing 409 carriers to the 3,007 non-ASD offspring devoid of ultra-rare deleterious variants in any of the 97 410 predicted MES genes (65 of 70 significant questions indicated carriers with heightened ASD-like 411 responses).

- In addition to examining individual SCQ questions, we assessed the total SCQ score. No discernible elevation in total scores was observed among carriers of any MES genes. The most substantial mean score difference between non-ASD carriers and non-carriers was less than two points. Nonetheless, our study demonstrated that non-ASD carriers of MES genes may exhibit significant differences in responses to specific SCQ questions, but not in overall scores. Nevertheless, our results suggest that individual MES genes can contribute to a mild social
- 418 deficiency phenotype.
- 419 Though ASD-related phenotype measurements were less abundant for non-ASD individuals, we 420 were able to evaluate the presence of other psychiatric or developmental conditions through the 421 basic medical questionnaire. Across 28,883 non-ASD individuals and 29 questions on the 422 presence of developmental or psychiatric conditions (e.g., schizophrenia, obsessive-compulsive 423 disorder, sleep disorders, motor delays), we found 47 of 97 tested MES genes exhibited a 424 significant (p<0.05) skew for at least one condition (Fig S7). In 83.6% of cases, carriers of the 425 MES gene showed increased incidence of the condition. For example, 15.5% of non-ASD 426 carriers of ultra-rare deleterious variants in *PITX3* reported obsessive-compulsive disorder 427 (OCD) compared to 4.3% of non-carriers (p=0.004). Of note, the minority of cases where MES 428 gene carriers had significantly lower incidence occurred exclusively for conditions that were 429 relatively common (>5% of non-ASD respondents) such as depression and social anxiety. 430 Again, these results were consistent when comparing to non-ASD offspring devoid of ultra-rare 431 deleterious variants in any of the 97 predicted MES genes. In summary, we found evidence that 432 many individual MES genes may contribute independently to specific ASD-related traits and 433 conditions in non-ASD carriers.
- 434


### 435 Phenotypes of ASD carriers of MES genes

The heightened prevalence of psychiatric conditions in non-ASD carriers of individual MES genes suggests a potential influence on the diverse presentation of ASD. It is conceivable that MES genes contribute to both the overall liability of ASD and the liability of comorbid symptoms associated with ASD. In the SPARK v1 cohort, 99.95% of individuals with ASD exhibit at least one of the 29 comorbid disorders assessed. Notably, language delays are the most common, affecting 51% of individuals, followed by attention-deficit/hyperactivity disorder (ADHD) at 38%.

Among 58 of the 97 MES genes analyzed, carriers with ASD displayed significantly altered frequencies of comorbid disorders compared to ASD individuals without any MES genes (**Fig** 

444 **3A**). For 31 MES genes, comorbid disorders were always more prevalent. For instance, 445 individuals with ASD carrying an ultra-rare deleterious variant in the gene NPM3 demonstrated 446 a significantly higher incidence of motor delay (p=0.002), diagnosed sleep disorders (p=0.007), 447 separation anxiety (p=0.02), social communication disorder (p=0.02), eating disorders (p=0.02), 448 and encopresis (p=0.03). Importantly, carriers of NPM3 among non-ASD individuals also exhibited a significantly higher incidence of learning disabilities (p=0.01) and separation anxiety 449 450 (p=0.04). In total, among the 31 MES genes associated with increased comorbidity frequency in 451 individuals with ASD, 14 were also linked to increased comorbidity frequency in non-ASD 452 individuals, though not always for the same comorbidity.

453



455 **Figure 3**. **Phenotypes and familial inheritance of MES genes.** (A) Differences in comorbidity frequency 456 of carriers of MES genes with ASD. Significant differences in ASD carrier versus non-carrier condition

457 frequencies are highlighted. Only genes with at least one significant comorbidity bias are shown. (B) 458 Example families from SPARK v1 that carry mutations in *SNAP25*. (C) As in panel B for *DUSP1*. (E) As in 450 panel B for *SLC*842.

- 459 panel B for *SLC8A2*.
- 460

- 461
- 462

463 Interestingly, for 17 MES genes, individuals with ASD exclusively exhibited significantly lower 464 incidence of comorbidities (Fig 3A). Carriers of ultra-rare deleterious variants in AVP, the gene 465 responsible for the production of the neuropeptide hormone arginine vasopressin, demonstrated 466 a reduced incidence of ADHD ( $p=5x10^{-4}$ ), sleep disorders (p=0.004), OCD (p=0.03), motor 467 delays (p=0.03), and learning disabilities (p=0.048). Notably, in non-ASD individuals, carriers of 468 AVP exhibited a decreased incidence of depression (p=0.02) and a noteworthy, albeit not statistically significant, decrease in ADHD and sleep disorders. As AVP is anxiogenic and 469 promotes the stress response <sup>27</sup>, we tangentially hypothesize its disruption could reduce these 470 effects. In addition, a further 10 MES genes showed increased frequencies for one comorbidity 471 472 while decreased frequency for another. Carriers of DRGX, a gene involved in nervous system 473 development, showed elevated incidence of social anxiety disorder (p=0.03), depression 474 (p=0.049), and Tourette Syndrome (p=0.04) but a decreased incidence of language delay 475 (p=0.01). Thus, we find evidence MES genes can both contribute to the genetic liability of ASD 476 and its heterogeneity.

477 478

#### 479 Co-expression and interactions of MES gene pairs

480

481 Above, we demonstrated that 76 of the 97 identified MES genes exhibited discernible 482 phenotypic associations, suggesting most MES genes do not form dependent interactions when 483 contributing to ASD risk. To further test dependence, we inquired into the co-expression and 484 protein interaction patterns of these MES gene pairs compared to random MES gene pairings.

485

486 Employing the tissue-based expression data used above, we found that for 48 of 50 gene pairs, 487 the correlation in tissue co-expression did not significantly surpass that observed between any 488 two MES genes (Fig S8A). Notably, only the paired genes CADM3 and OLIG1 demonstrated a 489 significantly elevated co-expression correlation (p=0.028; Pearson's r= 0.46). However, carriers 490 of CADM3 demonstrated altered SCQ responses, suggesting the pair's high co-expression is 491 not compelling evidence of dependence. Interestingly, the other gene pair with significant co-492 expression, CACNG8 and ZNF558, was anti-correlated (p=0.032; r= -0.38). Using the 493 expression profiles of 193 brain subregions, we also found three pairs demonstrated 494 significantly elevated co-expression and three pairs with significant anti-correlation (Fig S9A). 495 Interestingly, one of these significantly anti-correlated pairs was CADM3 and OLIG1 (p= 0.012, 496 r= -0.72) indicating their cross-tissue expression pattern was alike while their brain subregion 497 pattern was opposing. Together, we do not find evidence that paired MES genes are more co-498 expressed than any two MES genes, suggesting the pairs predominantly contribute 499 independently to ASD risk.

500

501 We additionally clustered MES co-expression patterns and compared them to 185 high 502 confidence ASD genes<sup>4</sup>. We found that MES genes did not cluster separately from these 503 established ASD genes, suggesting that MES genes integrate into similar tissue-expression 504 pathways (Fig S8B). This same finding was also observed using the expression from 193 brain 505 subregions (Fig S9B).

506

We additionally investigated protein-protein interactions between paired MES genes using 507 508 STRING  $(v12)^{28}$ . Of the 97 MES genes, 40 interacted with some second MES gene with 509 medium confidence (interaction score  $\geq 0.4$ ). However, only one MES pair, HMGA2 and CCK, 510 showed evidence of interaction (score=0.44). This again supports our hypothesis that MES pair 511 genes do not form dependent interactions.

- 512
- 513

### 514

### 515 Illustrative examples of MES gene pairs

516 Within this investigation, we have delineated the identification of 97 MES genes in 50 pairs, 517 exploring their connections to brain expression patterns and ASD-like phenotypes. To conclude, 518 we will highlight specific MES genes in these pairs, with particular attention given to familial 519 case studies. These cases not only underscore the significance of inheriting multiple MES 520 genes but also highlight the disparate contributions of MES genes to the genetic susceptibility of 521 ASD.

522 The concurrent inheritance of ultra-rare deleterious variants in SNAP25 (Synaptosome Associated Protein 25) and SLPI (Secretory Leukocyte Peptidase Inhibitor) emerged as a robust 523 association with ASD (equilibrium probability of 6.9x10<sup>-6</sup>; Bayes factor of 400). SNAP25, a 524 synaptic protein, is one of the highest expressed genes in the brain. While variants in SNAP25 525 526 have been linked to ADHD, schizophrenia, bipolar disorder, and neurodevelopmental disorders, it often fails to be linked to ASD <sup>3,4,29,30</sup>. Our findings support this inconsistency as loss-of-527 528 function disruptions of one copy of SNAP25 did not always coincide with ASD, best exemplified 529 by an inherited frameshift variant in a non-ASD mother transmitted to her child with ASD (Fig 530 **3B**). This suggests that meeting the genetic liability for ASD among SNAP25 carriers 531 necessitates additional contributions from common variations or another MES gene. In the case 532 of the mother-to-son transmitted frameshift in SNAP25, the ASD-afflicted child, but not the 533 mother, harbored an ultra-rare deleterious variant in another MES gene. DRGX, implicated in nervous system development. SLPI, another candidate paired with SNAP25 (Fig 3B), is integral 534 535 to the innate immune system and serves a protective role against inflammation in tissues <sup>31</sup>. 536 Notably, this candidate assumes relevance given the well-established association between inflammatory conditions and ASD 32,33. 537

538

Another noteworthy candidate MES gene is DUSP1 (Dual Specificity Phosphatase 1), a gene 539 implicated in the regulation of inflammation and nervous system development <sup>34</sup>. Our 540 541 investigation revealed a strong association of DUSP1 with ASD when co-occurring with 542 HIST1H4J (H4 Clustered Histone 11; H4C11) or PSMC3 (Proteasome 26S Subunit, ATPase 3), 543 with both genes linked to intellectual disability and neurodevelopmental delay <sup>35,36</sup>. Interestingly, 544 the concurrent inheritance of ultra-rare deleterious variants in PSMC3 and HISTH4J was 545 observed in only two individuals—a non-ASD mother and her son with ASD (Fig 3C). Though a 546 limited occurrence, this raises the possibility that *PSMC3* and *HISTH4J* may have comparatively 547 lesser contributions to the genetic liability of ASD when compared to DUSP1. This inference is 548 reinforced by the familial context, as the son with ASD inherited a DUSP1 variant from the father 549 in addition to the PSMC3 and HISTH4J variants from the mother. This unique familial pattern 550 suggests a more prominent role for DUSP1 in the manifestation of ASD within this specific 551 genetic context.

552

553 The last candidate MES genes we will illustrate are SLC8A2 (Solute Carrier Family 8 Member A2) which associates with ASD when paired with either TERF2 (Telomeric Repeat Binding 554 555 Factor 2) or GK5 (Glycerol Kinase 5) (Fig 3D). SLC8A2, a sodium-calcium exchanger, is highly expressed in neurons where it plays a role in sodium and calcium ion homeostasis<sup>37</sup>. TERF2 556 plays an important role in telomere maintenance and neuronal differentiation <sup>38</sup> whereas *GK5* is 557 558 a broadly expressed gene that is part of glycerol metabolism. The concurrent inheritance of 559 ultra-rare deleterious variants in TERF2 and GK5 was observed in four individuals - two with 560 and two without ASD. Three of these individuals were in the same family where variants in both 561 genes were transmitted from a non-ASD father to his two daughters with ASD (Fig 3D). However, as was observed above with DUSP1, PSMC3, and HISTH4J, the daughters with ASD 562

also inherited variants in *SLC8A2* from the mother. This case study again suggests that
 *SLC8A2* has a greater contribution to the genetic liability of ASD than *TERF2* and *GK5*. In
 summation, the interplay of our predicted MES genes underscores the polygenic landscape of
 genetic factors contributing to ASD susceptibility and heterogeneity.

567

568

### 569

### 570 **Discussion** 571

572 This study presents a novel approach to understanding the complex genetic landscape of ASD 573 by identifying MES genes – genes that individually, when harboring a deleterious variant, fall 574 below the ASD liability threshold but, when paired with another MES gene, collectively 575 contribute to ASD risk. By analyzing familial inheritance patterns of ultra-rare deleterious 576 variants, we identified candidate pairs of genes further assessed in 255,883 individuals of which 577 31,183 have ASD. We revealed 97 predicted MES genes forming 50 pairs, with significant 578 associations to ASD when considered together but not individually. This study emphasized the 579 importance of gene combinations, shedding light on the nuanced interplay of genetic factors in 580 ASD susceptibility and providing insights into the disorder's heterogeneity. Additionally, we 581 explored the expression profiles of MES genes in the brain and examined the phenotypic effects 582 of carriers, offering a comprehensive perspective on the multifaceted genetic contributions to 583 ASD.

584

585 Our study focused on identifying a novel but limited set of paired MES genes with the most pronounced associations to ASD. A primary limitation of this study is that we did not consider 586 587 common genetic variation or environmental conditions, assuming that the co-inheritance of 588 paired MES genes alone was sufficient to result in ASD. However, it is well-established that 589 common genetic variation and environmental factors substantially contribute to ASD liability. 590 Further analyses of MES or even large effect size genes may involve comparing carriers with high or low polygenic risk scores, potentially revealing that single MES genes and a high burden 591 592 of common variation may be adequate to cross the diagnostic threshold. The incorporation of 593 common variation may also aid in uncovering even smaller effect size genes. Detecting 594 combinations of three or more genes using our methodology would necessitate a larger number 595 of families. However, identifying smaller effect size genes conditioned on a high or low 596 polygenic risk score remains an avenue for future exploration.

597

598 Our investigation sought evidence for whether identified MES genes act independently or 599 participate in dependent GxG interactions to influence ASD susceptibility. SCQ responses 600 among non-ASD carriers revealed a significant skew for specific questions, suggesting that 601 many individual MES genes may independently contribute to subtle social deficiencies. 602 Furthermore, altered frequencies of developmental or psychiatric conditions in both non-ASD 603 and ASD carriers supported the notion that MES genes can independently influence diverse phenotypic outcomes. In total, 76 out of the 97 predicted MES genes exhibited skewed 604 605 frequencies in at least one SCQ response or the incidence of a developmental or psychiatric 606 condition. It is plausible that some MES gene pairs form dependent GxG interactions, implying 607 carriers of one gene exhibit no discernable differences from non-carriers. Notably, there were 608 instances where non-ASD individuals harbored ultra-rare deleterious variants in up to five MES 609 genes. MES gene burden in non-ASD individuals was not associated with sex at birth, 610 suggesting this is not a result of the female protective effect. Instead, in cases where non-ASD 611 individuals possessed more than two MES genes, the 21 genes without a skewed frequency in 612 SCQ or developmental/psychiatric conditions constituted an average of 90% of the multiple 613 MES genes per individual. If dependent GxG interactions describe this minority of genes, it

614 would allow non-ASD individuals to carry multiple unpaired MES genes without affecting their

615 phenotype. This nuanced understanding of the independent and collective actions of MES

genes provides insights into the intricate nature of their contributions to ASD susceptibility,

617 unraveling the complex interplay between genetics and phenotypic expression.

618

619 We hypothesized that MES genes would exhibit less conservation than larger effect size genes 620 which was indeed reflected by their moderate pLI deciles. In the context of ASD, genes with 621 large effect sizes typically manifest autosomal-dominant effects, leading to profound phenotypes 622 such as epilepsy, developmental delay, and intellectual disability, alongside ASD<sup>3</sup>. 623 Consequently, *de novo* mutations in these genes are seldom transmitted to subsequent 624 generations. In contrast, loss-of-function mutations in MES genes tend to result in less severe 625 phenotypes if any, possibly due to redundant pathways or functional paralogs. As a result, 626 disruptions in these genes can be transmitted and still contribute to the heritability of ASD. The 627 high heritability of ASD implies that its key genetic factors may generally be subject to more 628 lenient evolutionary constraints. Variants in genes that tolerate altered function and expression 629 may follow similar trends. The ability of MES genes to tolerate mutations and still contribute to 630 ASD's heritability underscores the importance of understanding the interplay between genetic 631 variation, phenotypic outcomes, and evolutionary pressures in the context of ASD susceptibility. 632 633 The most challenging aspect of MES genes is that the disruption of a single gene is generally 634 inadequate to induce ASD, yet still contributes to its etiology and heterogeneity. This 635 necessitates a nuanced approach in determining how terms such as "causal genes," "risk 636 genes," or "pathogenic variants" are to be applied. In the context of monogenic diseases, the

causality of a gene or mutation is often straightforward and direct. However, the causality
 associated with complex diseases like ASD entails a combination of multiple genetic variants

639 and environmental factors contributing to the progression of the condition, rather than merely 640 elevating the risk. Although a MES gene may be considered causal as it influences key 641 pathways in ASD development, it does not singularly determine the condition. Guidelines, such 642 as those established by the American College of Medical Genetics and Genomics (ACMG), play 643 a pivotal role in interpreting and categorizing genetic variants, ranging from pathogenic to 644 benign. ACMG incorporates an array of factors, including functional predictions, inheritance patterns, and prior reports, to assign pathogenicity to genes or variants <sup>39</sup>. This approach is 645 highly effective at identifying strong gene drivers of human diseases but less applicable to 646 647 complex conditions where MES genes may play crucial roles. Variants in MES genes may be 648 assigned as benign because they are not associated with a disorder, yet carrier status could be 649 clinically crucial such as predicting ASD recurrence or the likelihood of comorbidities. On the 650 other hand, assigning pathogenicity to these variants or genes is also an inaccurate term. This 651 complexity highlights a critical gap in the current genetic interpretation frameworks. As 652 researchers further study complex disorders (e.g., ADHD, OCD, bipolar disorder), there will be a

653 growing need to adapt or develop new guidelines to more accurately address the nuances of 654 polygenic diseases.

655 656

657

### 658 Methods

659

### 660 Family-based search for MES genes in SPARK

661

For our initial family-based screening of MES genes, we harnessed a dataset comprising 10,908
 families sourced from SPARK <sup>15</sup> iWES v1 (including sequencing waves WES1-WES4), in which
 both parents and at least one ASD offspring underwent sequencing via WES. All genotypes

were annotated with Ensembl Variant Effect Predictor (VEP) <sup>40</sup>. We excluded genotype calls 665 that did not adhere to Mendelian inheritance patterns within the family (accounting for an 666 average of 0.72% of variants), effectively eliminating de novo mutations. Furthermore, during 667 668 the initial screening phase, we omitted 113 families in which a proband exhibited a de novo rare deleterious variant (a PTV or a missense variant with a PolyPhen-2<sup>41</sup> score ≥0.5 or SIFT <sup>42</sup> 669 score  $\leq$  0.05; gnomAD v3<sup>16</sup> non-neuro allele frequency of <1%) in the genes CHD8, SCN2A, 670 671 SYNGAP1, SHANK3, or ADNP. These particular genes have a reported zero FDR for association with ASD from TADA<sup>4</sup>, signifying a strong and monogenic-like association with 672 673 ASD. Consequently, they were deemed unsuitable for the identification of MES genes. PTEN 674 was not removed for the screen as deleterious variants occurred in controls.

675

676 We isolated ultra-rare deleterious variants in the families (a PTV or a missense variant with a 677 PolyPhen-2 score  $\geq 0.5$  or SIFT score  $\leq 0.05$ ; gnomAD v3 non-neuro allele frequency of < 0.1%). Though many more missense pathogenicity estimators are available <sup>43</sup>, we opted for ones that 678 scored for protein function impact without emphasis on species conservation or gene constraint 679 680 (e.g., MPC<sup>44</sup>). Per our hypothesis, deleterious variants in single MES genes do not result in a strong phenotype and may not show as robust evidence of negative selection. For the same 681 682 reason, we did not exclude genes based on LOEUF or pLI score. Additionally, we only included 683 heterozygous genotypes on the reasoning that (1) homozygous combinations of ultra-rare 684 deleterious variants are effectively unobserved, and (2) individuals homozygous for deleterious

685 variants in a MES gene may have a separate non-ASD phenotype.

686

687 We first identified familial structures characterized by the inheritance of a specific ultra-rare 688 deleterious variant (denoted as 'A\*') by all offspring with ASD within the family, with 'A\*' also 689 being present in one non-ASD parent. Subsequently, we identified mirrored patterns of 690 inheritance, focusing on a second variant in a distinct gene ('B\*'). In such scenarios, 'B\*' must 691 derive from the parent who did not transmit 'A\*'. 'A\*B\*' must be present in all offspring with ASD 692 and never in non-ASD siblings. Importantly, our methodology accommodated the potential 693 existence of multiple 'A\*' or 'B\*' variants within the same gene in a single family. We quantified 694 these patterns based on the number of unique families, rather than unique sites. 695

We next assessed the likelihood of observing 'B\*' inheritance patterns within families exhibiting
'A\*' inheritance. For this, we conducted binomial samplings to estimate the number of times we
should observe any number of secondary independent gene hits:

699

$$N = \sum_{gene=1}^{n\_genes} B \sim Binom(A, M_{gene})$$

700

where B is the number of families with 'B\*' inheritance, A is the number of families with 'A\*' inheritance, and  $M_{gene}$  is the frequency of ultra-rare deleterious variants in a gene among the 21,570 non-ASD parents. This outputs N, the expected number of genes with B secondary hits given A.

705

Drawing from the frequency of ultra-rare deleterious variants per gene, calculated using parental
data, our aim was to standardize N, representing the expected number of genes with secondary
B hits, given A. Notably, larger genes, containing a higher occurrence of ultra-rare deleterious
variants, might bear reduced significance when compared to smaller genes with fewer such
variants. In our approach, for each pair of candidate MES genes, we multiplied N by the relative
frequency of ultra-rare deleterious variants in the respective genes, designated as 'N\_norm'.
The gene possessing the highest number of ultra-rare deleterious variants, *TTN*, would have an

713 adjustment of one with all other genes adjusted by factors less than one, contingent on their 714 relative frequency of ultra-rare deleterious variants to TTN. To illustrate, consider the case of 715 SNAP25 and SLPI. Among the families analyzed, five exhibited the 'A\*' inheritance pattern for 716 SNAP25, while 21 displayed the same for SLPI. Two families featured the mirrored 'A\*B\*' 717 inheritance pattern for both genes. According to binomial sampling, the occurrence of '5-given-2' 718 is expected approximately 15 times, whereas '21-given-2' should transpire approximately 196 719 times (before normalization). Due to their smaller gene sizes, SNAP25 and SLPI 720 correspondingly exhibited 'N norm' values of 0.061 and 0.174, indicating that the co-occurrence 721 of these two genes inherited together is relatively unexpected and thus included as a candidate

- pair for further investigation. We kept pairs where 'N\_norm' was less than one for both
- 723 configurations of gene pairs.
- 724 725

### 726 Additional variant types and frequencies

727 728 In addition to PTVs and missense variants of ultra-rare or rarer frequency, we tested three other 729 stringencies: PTVs and missense variants of rare (1%) or rarer frequency, only PTVs of ultra-730 rare (0.1%) and rarer frequency, and only PTVs of rare or rarer frequency. For PTVs and 731 missense variants of rare or rarer frequency, we retained 2,507 pairs of genes (2,146 total 732 unique genes) where the normalized expected frequency was less than one in both 'A\*' and 'B\*' 733 configurations. After filtering for non-ASD 'A\*B\*' in the SPARK v1 dataset, only 179 candidate 734 pairs remained (339 total unique genes). For PTVs of rare or rarer frequency, we retained 834 735 (1,336 total unique genes) candidate pairs of which only 83 (161 unique genes) remained after 736 SPARK filtering. For PTVs of ultra-rare or rarer frequency, we retained 692 candidate pairs 737 (1,177 total unique genes) of which only 63 (122 unique genes) remained after SPARK filtering. 738

### 739740 *Non-neuro cohorts*

741

We included variants from the 3,202 individuals from the 1000 genomes project (1kGP)<sup>17,18</sup>.
 SIFT scores, PolyPhen-2 scores, and allele frequencies were extracted from GnomAD
 (v3.1.2)<sup>45</sup>.

745 746 Analyses for All of Us were performed in the workspace titled "Detecting the prevalence of ultra-747 rare gene mutations." We selected samples with short read whole genome sequencing and 748 excluded individuals with a survey response diagnosis of ASD (diagnosed with, receiving 749 treatment for, or seeking treatment for ASD) or any disorder characterized under 'mental 750 disorder.' The final cohort included 156,550 individuals of which 50.5% were of a self-reported 751 non-white race and 57.0% were assigned female sex at birth. Due to the security constraints of the All of Us workbench, VEP was performed with SNPeff<sup>42</sup> (4.3t) as opposed to Ensembl. 752 753 GnomAD v3 frequencies, Polyphen-2 scores, and SIFT scores were acquired from dbNSFP(v4)<sup>47</sup>. 98.8% of missense variants had an available Polyphen-2 and SIFT score. For 754 high impact insertions and deletions that were not present in dbNSFP, we used the allele 755 756 frequency in the 156,550 individuals as a proxy. To avoid disseminating individual-level data, we did not report the precise number of individuals with 'A\*B\*' for any gene pair (unless zero or 757 758 greater than 20). For any single candidate gene, ultra-rare deleterious variants were always 759 present in at least 20 individuals.

760

We additionally included individuals from the BioMe Biobank maintained by the Mount Sinai
 Health System. We isolated 16,586 individuals with genotype information derived from WES
 and excluded any individuals with a diagnosed or self-reported mental, behavioral, or

neurodevelopmental disorders (ICD codes F01-F99). Of the final cohort, the mean age was 61.7
years, 56.2% were of self-reported male sex, and 56.9% were of self-reported non-white race.
For consistency, VEP was performed in an identical manner as for the All of Us cohort.

767 768

## 769 Equilibrium test and Bayes factors770

771 We determined the frequency of ultra-rare deleterious variants per gene across all samples, 772 encompassing both ASD and non-ASD individuals. The probability of 'A\*B\*' was computed as 773 the product of the individual gene frequencies. Using the R function 'pbinom,' we designated this 774 product as the probability of success for 'A\*B\*.' Subsequently, we calculated (1) the probability 775 of observing the given number or a greater number of ASD individuals with 'A\*B\*', considering 776 the total number of individuals with ASD, and (2) the probability of observing the given number or a lesser number of non-ASD individuals with 'A\*B\*' mutations, considering the total number of 777 778 individuals without ASD. The equilibrium probability was then determined as the product of 779 these two probabilities.

780

For the Bayes factor, the null hypothesis was the equilibrium probability, and the alternate
hypothesis was the probability of observing the given number or a greater number of individuals
regardless of ASD status with 'A\*B\*', considering the total number of individuals. The Bayes
factor was calculated as the ratio of alternate and null equilibrium probabilities.

785 786

### 787 Validation analyses

788 789 We procured ultra-rare synonymous variants across all cohorts, excluding those with a 790 functional impact (e.g., missense, or more significant effects) on another gene. Ultra-rare 791 synonymous variants were, on average, 1.83 times more frequent per gene than ultra-rare 792 deleterious variants, which underwent further filtration for deleteriousness via VEP. We 793 determined the ratio of ultra-rare synonymous to ultra-rare deleterious variants across all 794 protein-coding genes. As some genes presented markedly divergent ratios, we excluded those 795 beyond the >95th or <5th percentile thresholds. This adjustment predominantly impacted 796 smaller genes where variants were only observed in a few samples.

797

802

Using ultra-rare synonymous variants, the initial screening (steps 1-3 of Fig 2) identified 690
candidate gene pairs, significantly fewer than the 1,916 pairs identified with deleterious variants.
Subsequent analysis incorporating the complete SPARK v1 cohort (step 4 of Fig 2) further
narrowed the candidate pairs to 129 (258 unique genes).

803 In the SPARK v1 cohort, we noted outlier individuals with high counts of ultra-rare synonymous 804 variants. On average, the occurrence of ultra-rare synonymous variants was less than one per 805 individual per gene. Among 258 unique genes from 129 candidate pairs identified with 806 synonymous variants, four samples exhibited over 100 variants in single genes, 50-fold higher 807 than the mean (SP0122762, SP0379928, SP0149880, SP0064380; Fig S3D). The excess 808 synonymous variants in the four samples were unique and not cataloged in gnomAD v4, casting 809 doubts on their quality. Contrastingly, such an excess was not observed with ultra-rare 810 deleterious variants (Fig S3D). We subsequently removed these four samples from analyses. 811

For additional validation, we incorporated novel samples from SPARK iWES v2 (WES5). Quality control was identical to that of SPARK v1.

### 815

### 816 Gene expression

817

We used nTPM values derived from RNAseg from the Human Protein Atlas (v23)<sup>22</sup>. The 50 818 tissue consensus used transcriptomics from both the Human Protein Atlas and the GTEx 819 consortium <sup>48</sup>. Expression for the 193 brain subregions was also from the Human Protein Atlas. 820 821 To test if the 97 predicted MES genes were significantly enriched in a tissue or brain subregion, 822 we sampled genes from all protein coding genes without replacement in 1000 iterations. For 823 each iteration, we measured the fraction of sampled genes expressed (nTPM >1) in each tissue or brain subregion. We used the Shapiro–Wilk test<sup>49</sup> (R command 'shapiro.test') to confirm 824 825 sampled statistics were normally distributed (p>0.05). We then used the cumulative density 826 function of the normal distribution to determine the significance of predicted MES gene 827 enrichment per tissue or brain subregion.

828

Using the same two RNAseq datasets described above, we calculated the correlation of nTMP values across tissues and brain subregions. To assess the significance of MES pair coexpression, we calculated the co-expression correlation of all possible MES gene pairs and then calculated the p-value of real MES pairs using the R function 'pnorm'. Hierarchical clustering of the co-expression of MES and other ASD genes was performed with the R function 'hclust'

- using the 'ward.D2' method and plotted with 'ComplexHeatmap'<sup>50</sup>.
- 835 836

### 837 Phenotypes of MES carriers

We utilized the Social Communication Questionnaire (SCQ) and basic medical questionnaire
administered in the SPARK v1 cohort. For the SCQ total score, we removed 167 non-ASD
siblings with a score at or above 13 (two standard deviations above the mean among non-ASD
respondents). For the basic medical screening, we excluded questions related to birth defects
(as they were uncommon) and environmental exposures (e.g., lead poisoning, fetal alcohol
syndrome, traumatic brain injury).

- 845
- 846

### 847 Acknowledgements

848

The authors wish to thank Dr. David Cutler for insightful feedback on the manuscript and MarinaNatividad Avila for assistance with data access.

851

852 The All of Us Research Program is supported by the National Institutes of Health, Office of the 853 Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 854 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 855 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: 856 HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 857 858 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and 859 Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 860 OD025276. In addition, the All of Us Research Program would not be possible without the 861 partnership of its participants.

862

The BioMe Biobank is supported by The Charles Bronfman Institute for Personalized Medicine at Mount Sinai. We want to further thank all participants and families that were a part of the

865 research cohorts used in this research.

866

This study received funding from the Beatrice and Samuel A. Seaver Foundation (BM, JDB) and the National Institutes of Health (NIH), under grant numbers R01MH129724 (JDB, BM) and R01MH128813 (JDB).

870

### 871872 Author contributions

873

M.C. led the study design, conducted analyses, and authored the manuscript. B.M. contributed
to the study design and manuscript editing and, along with J.D.M., oversaw project
management. F.K.S. performed data generation and quality control related to the SPARK
cohort.

878

## 879880 Competing interests

- 882 The authors declare no competing interests.
- 883

881

#### 884 885 **Data availability**

- 886
- 887 Whole genome sequencing from 1kGP is freely available from The International Genome
- 888 Sample Resource (https://www.internationalgenome.org/). All other individual-level data used in
- this study are not publicly available with access permission subject to review. The genetic and
- 890 phenotypic data for SPARK can be requested at SFARI Base
- 891 (https://www.sfari.org/resource/spark/). Access to the Sinai BioMe data can be requested
- 892 through The Charles Bronfman Institute for Personalized Medicine
- 893 (https://icahn.mssm.edu/research/ipm/programs/biome-biobank) and is subject to compliance
- 894 with the Mount Sinai Health System's data use agreements. All of Us controlled tier data is
- available for registered institutions and cohort selection is detailed in the workbench titled"Detecting the prevalence of ultra-rare gene mutations."
- 897

### 898 899 **Code availability**

- 900
- 901 Code and resources used in this study is available on GitHub at
- 902 (https://github.com/MahjaniLab/MES\_Code). For any further inquiries or requests for code not 903 available in the repository, please contact the corresponding author.
- 904 905

### 906 References

- 907
  908 1. Klei, L. *et al.* Common genetic variants, acting additively, are a major source of risk for
- 909 autism. Mol. Autism 3, 9 (2012).

Caballero et al. 2024 | 21

- 910 2. Gaugler, T. et al. Most genetic risk for autism resides with common variation. Nat. Genet.
- **46**, 881–885 (2014).
- 912 3. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional
- 913 Changes in the Neurobiology of Autism. *Cell* **180**, 568-584.e23 (2020).
- 914 4. Fu, J. M. et al. Rare coding variation provides insight into the genetic architecture and
- 915 phenotypic context of autism. *Nat. Genet.* **54**, 1320–1331 (2022).
- 916 5. Bai, D. *et al.* Association of Genetic and Environmental Factors With Autism in a 5-Country
  917 Cohort. *JAMA Psychiatry* **76**, 1035–1043 (2019).
- 918 6. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder.
- 919 *Nat. Genet.* **51**, 431–444 (2019).
- 920 7. Modabbernia, A., Velthorst, E. & Reichenberg, A. Environmental risk factors for autism: an
  921 evidence-based review of systematic reviews and meta-analyses. *Mol. Autism* 8, 13 (2017).
- 8. Sandin, S. *et al.* The Heritability of Autism Spectrum Disorder. *JAMA* 318, 1182–1184
  (2017).
- 924 9. Rylaarsdam, L. & Guemez-Gamboa, A. Genetic Causes and Modifiers of Autism Spectrum
  925 Disorder. *Front. Cell. Neurosci.* 13, 385 (2019).
- 926 10. De Rubeis, S. *et al.* Synaptic, transcriptional and chromatin genes disrupted in autism.
  927 *Nature* 515, 209–215 (2014).
- 928 11. Sanders, S. J. *et al.* Insights into Autism Spectrum Disorder Genomic Architecture and
  929 Biology from 71 Risk Loci. *Neuron* 87, 1215–1233 (2015).
- 930 12. He, X. *et al.* Integrated Model of De Novo and Inherited Genetic Variants Yields Greater
  931 Power to Identify Risk Genes. *PLOS Genet.* 9, e1003671 (2013).
- 13. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536,
  285–291 (2016).
- 14. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in
- 935 141,456 humans. *Nature* **581**, 434–443 (2020).

Caballero et al. 2024 | 22

- 936 15. SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research. *Neuron* 97, 488–
  937 493 (2018).
- 16. Siwei Chen et al. A genome-wide mutational constraint map quantified from variation in
- 939 76,156 human genomes. *bioRxiv* 2022.03.20.485034 (2022)
- 940 doi:10.1101/2022.03.20.485034.
- 17. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
- 18. Byrska-Bishop, M. *et al.* High-coverage whole-genome sequencing of the expanded 1000

943 Genomes Project cohort including 602 trios. *Cell* **185**, 3426-3440.e19 (2022).

- 19. Sasani, T. A. *et al.* Large, three-generation human families reveal post-zygotic mosaicism
- and variability in germline mutation accumulation. *eLife* **8**, e46922 (2019).
- 20. lossifov, I. *et al.* The contribution of de novo coding mutations to autism spectrum disorder.
- 947 *Nature* **515**, 216–221 (2014).
- 948 21. Taniya, M. A. et al. Role of Gut Microbiome in Autism Spectrum Disorder and Its

949 Therapeutic Regulation. *Front. Cell. Infect. Microbiol.* **12**, 915701 (2022).

- 22. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
- 951 23. Gao, J. et al. Alteration of peripheral cortisol and autism spectrum disorder: A meta-
- 952 analysis. *Front. Psychiatry* **13**, 928188 (2022).
- 24. Al-Zaid, F. S., Alhader, A. F. A. & Al-Ayadhi, L. Y. A potential role for the adrenal gland in
  autism. *Sci. Rep.* 11, 17743 (2021).
- 25. Cai, J. & Tong, Q. Anatomy and Function of Ventral Tegmental Area Glutamate Neurons. *Front. Neural Circuits* 16, 867053 (2022).
- 957 26. Seguin, D. et al. Amygdala subnuclei volumes and anxiety behaviors in children and
- adolescents with autism spectrum disorder, attention deficit hyperactivity disorder, and
- obsessive–compulsive disorder. *Hum. Brain Mapp.* **43**, 4805–4816 (2022).
- 960 27. Beurel, E. & Nemeroff, C. B. Interaction of stress, corticotropin-releasing factor, arginine
- 961 vasopressin and behaviour. *Curr. Top. Behav. Neurosci.* **18**, 67–80 (2014).

Caballero et al. 2024 | 23

- 962 28. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased
- 963 coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic*

964 Acids Res. 47, D607–D613 (2019).

- 965 29. Antonucci, F. et al. SNAP-25, a Known Presynaptic Protein with Emerging Postsynaptic
- 966 Functions. *Front. Synaptic Neurosci.* **8**, 7 (2016).
- 967 30. Corradini, I., Verderio, C., Sala, M., Wilson, M. C. & Matteoli, M. SNAP-25 IN
- 968 NEUROPSYCHIATRIC DISORDERS. Ann. N. Y. Acad. Sci. 1152, 93–99 (2009).
- 969 31. Doumas, S., Kolokotronis, A. & Stefanopoulos, P. Anti-Inflammatory and Antimicrobial Roles
- 970 of Secretory Leukocyte Protease Inhibitor. *Infect. Immun.* **73**, 1271–1274 (2005).
- 971 32. Siniscalco, D., Schultz, S., Brigida, A. L. & Antonucci, N. Inflammation and Neuro-Immune
- 972 Dysregulations in Autism Spectrum Disorders. *Pharmaceuticals* **11**, 56 (2018).
- 973 33. Arteaga-Henríquez, G., Gisbert, L. & Ramos-Quiroga, J. A. Immunoregulatory and/or Anti-
- 974 inflammatory Agents for the Management of Core and Associated Symptoms in Individuals
- 975 with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled
- 976 Trials. CNS Drugs **37**, 215–229 (2023).
- 977 34. Pérez-Sen, R. *et al.* Dual-Specificity Phosphatase Regulation in Neurons and Glial Cells.
- 978 Int. J. Mol. Sci. 20, 1999 (2019).
- 979 35. Ebstein, F. et al. PSMC3 proteasome subunit variants are associated with
- 980 neurodevelopmental delay and type I interferon production. *Sci. Transl. Med.* **15**, eabo3189
  981 (2023).
- 36. Tessadori, F. *et al.* Recurrent de novo missense variants across multiple histone H4 genes
  underlie a neurodevelopmental syndrome. *Am. J. Hum. Genet.* **109**, 750–758 (2022).
- 984 37. Spencer, S. A., Suárez-Pozos, E., Escalante, M., Myo, Y. P. & Fuss, B. Sodium-calcium
- 985 exchangers of the SLC8 family in oligodendrocytes: Functional properties in health and
- 986 disease. *Neurochem. Res.* **45**, 1287–1297 (2020).

Caballero et al. 2024 | 24

- 38. Grammatikakis, I., Zhang, P., Mattson, M. P. & Gorospe, M. The long and the short of TRF2
  in neurogenesis. *Cell Cycle* 15, 3026–3032 (2016).
- 989 39. Richards, S. et al. Standards and Guidelines for the Interpretation of Sequence Variants: A
- 990 Joint Consensus Recommendation of the American College of Medical Genetics and
- 991 Genomics and the Association for Molecular Pathology. *Genet. Med. Off. J. Am. Coll. Med.*
- 992 *Genet.* **17**, 405–424 (2015).
- 40. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 41. Adzhubei, I. A. *et al.* A method and server for predicting damaging missense mutations. *Nat.*
- 995 *Methods* **7**, 248–249 (2010).
- 42. Sim, N.-L. *et al.* SIFT web server: predicting effects of amino acid substitutions on proteins.
- 997 *Nucleic Acids Res.* **40**, W452–W457 (2012).
- 998 43. Dong, C. et al. Comparison and integration of deleteriousness prediction methods for
- 999 nonsynonymous SNVs in whole exome sequencing studies. Hum. Mol. Genet. 24, 2125-
- 1000 2137 (2015).
- 44. Kaitlin E. Samocha *et al.* Regional missense constraint improves variant deleteriousness
  prediction. *bioRxiv* 148353 (2017) doi:10.1101/148353.
- 45. Chen, S. *et al.* A genome-wide mutational constraint map quantified from variation in 76,156
  human genomes. 2022.03.20.485034 Preprint at https://doi.org/10.1101/2022.03.20.485034
  (2022).
- 1006 46. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide
- 1007 polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-
- 1008 2; iso-3. *Fly (Austin)* **6**, 80–92 (2012).
- 1009 47. Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of
- 1010 transcript-specific functional predictions and annotations for human nonsynonymous and
- 1011 splice-site SNVs. *Genome Med.* **12**, 103 (2020).

Caballero et al. 2024 | 25

- 1012 48. THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across
- 1013 human tissues. *Science* **369**, 1318–1330 (2020).
- 1014 49. SHAPIRO, S. S. & WILK, M. B. An analysis of variance test for normality (complete
- 1015 samples)†. *Biometrika* **52**, 591–611 (1965).
- 1016 50. Gu, Z. Complex heatmap visualization. *iMeta* **1**, e43 (2022).